← Human Trials & Peer-Reviewed Studies
Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis
Plain-language guide to PMID 21095149 (2011): double-blind randomized controlled trial study of Parathyroid Hormone (PTH 1-84) in 119 women, osteoporosis and bone density.
Key Facts
- PMID
- 21095149
- Journal
- Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Schafer AL et al. (6 authors)
- DOI
- 10.1016/j.jocd.2010.09.001
What This Study Did, in Plain Language
What Was Tested
Researchers studied Parathyroid Hormone (PTH 1-84) in the context of osteoporosis and bone density in this randomized controlled trial publication.
Baseline and follow-up procollagen type I N propeptide (PINP), bone-specific alkaline phosphatase (BAP), C-terminal telopeptide (CTX), and serum and urinary calcium levels were analyzed post hoc from the 119 postmenopausal women with osteoporosis randomized to PTH(1-84) in the Parathyroid Hormone and Alendronate trial.
Who Took Part
The abstract describes 119 women taking part.
PubMed indexes the participants as middle-aged adults and older adults, women only.
How the Study Was Run
The design is described as randomized and double-blind.
Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.
Blinding on both sides kept the women and researchers unaware of who received Parathyroid Hormone (PTH 1-84).
What Was Measured
Baseline and follow-up procollagen type I N propeptide (PINP), bone-specific alkaline phosphatase (BAP), C-terminal telopeptide (CTX), and serum and urinary calcium levels were analyzed post hoc from the 119 postmenopausal women with osteoporosis randomized to PTH(1-84) in the Parathyroid Hormone and Alendronate trial.
Topics PubMed links to this paper include Alendronate, Alkaline Phosphatase, Biomarkers, Bone Density, Bone Density Conservation Agents, Bone and Bones and Calcium.
What This Means in Plain Language
The paper is a randomized and double-blind study of Parathyroid Hormone (PTH 1-84) in 119 women in people with osteoporosis and bone density.
The publication is from 2011 (Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry), a journal based in United States.
More context: the Parathyroid Hormone (PTH 1-84) compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.